A novel anti‑EGFR monoclonal antibody (EMab‑17) exerts antitumor activity against oral squamous cell carcinomas via antibody‑dependent cellular cytotoxicity and complement‑dependent cytotoxicity

Junko Takei(Tohoku University), Yukinari Kato(Tohoku University)
Oncology Letters
February 10, 2020
Cited by 22


Related Papers